Pept-insTM selectively induce aggregation of their target protein(s), resulting in loss of function.
PEPT-INSTM : a new modality in drug development
Aelin Therapeutics develops first-in-class drugs based on the Pept-inTM technology platform.
These peptide-based biologicals distinguish themselves from existing therapeutic approaches:
Unique mode of action
Designability
Their specificity can be rationally tailored to either a single protein specifically or an entire family.
Novel intracellular target space
Proteins can be targeted independent of their structural or functional class, (sub)cellular location and without restrictions to epitopes/defined active sites.
Preparing for the post-antibiotic era
Around the world bacteria are developing new strategies that render them resistant to existing antibiotics. Most current antibiotics work according to only a few mechanisms of action and so when a bacterium becomes tolerant to one drug, it often becomes tolerant to the whole family. What we need is an entirely new class of drugs that shares no structural or mechanistic similarities with the existing antibiotics. Pept-insTM can treat antibiotic-resistant Gram-negative bacterial infections by inducing toxic protein aggregation within bacterial cells. By harnessing this novel mechanism of action, Aelin Therapeutics could circumvent growing resistance to existing antibiotics.
DISCOVER THEIR ANTIBACTERIAL POTENTIAL
Drug the undruggable
Aelin Therapeutics will develop Pept-insTM against high-value undruggable human targets in other disease fields such as oncology. Pept-insTM can also overcome the traditional challenges that labelled some targets undruggable. By exploiting its unique mode of action, its designability and intracellular target space, Aelin Therapeutics will tackle those targets for which existing drug modalities are failing.
SEE HOW THEY CAN RESOLVE MEDICAL CHALLENGES
Drug the undruggable
Aelin Therapeutics will develop Pept-insTM against high-value undruggable human targets in other disease fields such as oncology. Pept-insTM can also overcome the traditional challenges that labelled some targets undruggable. By exploiting its unique mode of action, its designability and intracellular target space, Aelin Therapeutics will tackle those targets for which existing drug modalities are failing.
SEE HOW THEY CAN RESOLVE MEDICAL CHALLENGES
Unlimited potential
Beyond these valuable applications, Pept-insTM represent a technology platform for the rational design of novel therapeutics. The unexplored target space is immense. Broad applicability has already been demonstrated with proofs of concept in functional knock-down of mammalian, bacterial, viral, and fungal protein targets for treatment of human diseases.
OUR PIPELINE
THE COMPANY
Aelin Therapeutics is a privately held Belgian company, founded in 2017 as a spin-off of the VIB and its partner universities KU Leuven, VUB and UGent. The company secured a 27 M Euro Series A investment by a very reputable investor syndicate. The company has a scientific and management team with a solid track record.
